Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.46 |
| ▸ | MEN1 | O00255 | 7/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PLIN5 | Q00G26 | 1/20 | 0.46 |
| ▸ | ABHD5 | Q8WTS1 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.37 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.37 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL490159 | 0.77 | LIPG (0.36) | KMT2AMEN1LMNAALDH1A1HPGD | |
| SCHEMBL489388 | 0.77 | KMT2A (0.43) | MAPTKMT2AMEN1LMNAPLIN1 | |
| SCHEMBL14991937 | 0.74 | ALDH1A1 (0.53) | MAPTKMT2AMEN1LMNAPOLB | |
| SCHEMBL14992050 | 0.74 | ALDH1A1 (0.53) | MAPTKMT2AMEN1LMNAPOLB | |
| SCHEMBL14991821 | 0.74 | ALDH1A1 (0.53) | MAPTKMT2AMEN1LMNAPOLB | |
| SCHEMBL14992857 | 0.74 | ALDH1A1 (0.53) | MAPTKMT2AMEN1LMNAPOLB | |
| SCHEMBL14992494 | 0.72 | ALDH1A1 (0.51) | MAPTKMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL7273337 | 0.71 | MAPT (0.60) | MAPTKMT2AMEN1LMNAPLIN1 | |
| SCHEMBL10847138 | 0.71 | MAPT (0.60) | MAPTKMT2AMEN1LMNAPLIN1 | |
| SCHEMBL10756378 | 0.71 | KMT2A (0.86) | MAPTKMT2AMEN1LMNAPLIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1515723-B1 | SUBSTITUTED DIHYDROPYRIMIDONES AND DIHYDROPYRIMIDINETHIONES AS CALCIUM CHANNEL BLOCKERS | VITTAL MALLYA SCIENT RES FOUNDATION (IN) | 2014-02-12 | — | — | EP | disclosed |
| US-8106062-B1 | Calcium channel blockers | DIAKRON PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-7687511-B2 | Substituted dihydropyrimidines, dihydropyrimidones and dihydropyrimidinethiones as calcium channel blockers | PULLELA PHANI KUMAR | 2010-03-30 | — | — | US | disclosed |
| US-20080125449-A1 | SUBSTITUTED DIHYDROPYRIMIDINES, DIHYDROPYRIMIDONES AND DIHYDROPYRIMIDINETHIONES AS CALCIUM CHANNEL BLOCKERS | PULLELA PHANI KUMAR | 2008-05-29 | — | — | US | disclosed |
| EP-1542683-A2 | CALCIUM CHANNEL BLOCKERS | Diakron Pharmaceuticals, Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| EP-1515723-A2 | SUBSTITUTED DIHYDROPYRIMIDONES AND DIHYDROPYRIMIDINETHIONES AS CALCIUM CHANNEL BLOCKERS | VITTAL MALLYA SCIENTIFIC RESEARCH FOUNDATION (IN) | 2005-03-23 | — | — | EP | disclosed |
| WO-2004024153-A2 | CALCIUM CHANNEL BLOCKERS | DIAKRON PHARMACEUTICALS, INC. (US) | 2004-03-25 | — | — | WO | disclosed |
| US-20040058942-A1 | Substituted dihydropyrimidines, dihydropyrimidones and dihydropyrimidinethiones as calcuim channel blockers | PULLELA PHANI KUMAR (US) | 2004-03-25 | — | — | US | disclosed |
| WO-2003105854-A2 | SUBSTITUTED DIHYDROPYRIMIDINES, DIHYDROPYRIMIDONES AND DIHYDROPYRIMIDINETHIONES AS CALCIUM CHANNEL BLOCKERS | VITTAL MALLYA SCIENTIFIC RESEARCH FOUNDATION (IN) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125449-A1 | SUBSTITUTED DIHYDROPYRIMIDINES, DIHYDROPYRIMIDONES AND DIHYDROPYRIMIDINETHIONES AS CALCIUM CHANNEL BLOCKERS | ORAI1, RYR2, RYR1 | MAPT 1688/4885KMT2A 3863/4885MEN1 3634/4885 |
| US-20040058942-A1 | Substituted dihydropyrimidines, dihydropyrimidones and dihydropyrimidinethiones as calcuim channel blockers | ORAI1, CACNA1B, CACNA1I | MAPT 2360/4885KMT2A 4216/4885MEN1 3305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.